Curis. has been granted a patent for methods that involve administering compounds to inhibit VISTA and PD-1 pathways alongside TIM-3 and PD-1 pathways. This approach aims to treat disorders by counteracting immunosuppressive signals associated with these pathways, particularly in cancer patients. GlobalData’s report on Curis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Curis Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Curis, Cancer treatment biomarkers was a key innovation area identified from patents. Curis's grant share as of July 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

Cancer treatment using compounds that inhibit immune checkpoints

Source: United States Patent and Trademark Office (USPTO). Credit: Curis Inc

The granted patent US12064418B2 outlines a method for treating cancer by conjointly administering two compounds to a subject in need of treatment. The claims specify that the first and second compounds can be various pharmaceutical agents, including their pharmaceutically acceptable salts. The patent encompasses a wide range of cancers that can be targeted by this method, including but not limited to small cell lung cancer, multiple myeloma, bladder carcinoma, ovarian carcinoma, and various other malignancies affecting different organs and systems in the body. The claims also detail specific types of cancers, such as breast cancer, colon cancer, and non-Hodgkin's lymphoma, among others.

The method described in the patent emphasizes the versatility of the treatment approach, allowing for the targeting of numerous cancer types through the administration of the specified compounds. The claims highlight the potential for this method to address both solid tumors and hematological malignancies, indicating a broad applicability in oncology. By identifying a range of cancers, the patent suggests that the treatment could be beneficial for a diverse patient population, potentially improving therapeutic outcomes in cancer care.

To know more about GlobalData’s detailed insights on Curis, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies